admin – Page 2773 – Get News Story

AV Access Launches iDock B10: A Cutting-Edge 8K Dual Monitor KVM Switch Docking Station for Home Office & Gaming

““AV Access is proud to introduce the iDock B10 8K KVM switch docking station, designed for video editors, graphic designers, and gamers. As demand grows for multi-PC and multi-monitor setups, this all-in-one device empowers users to efficiently manage a desktop, a laptop, dual 8K monitors, and a wide range of peripherals with ease.” — Bill Liao, CTO of AV Access”

AV Access introduces the iDock B10, a powerful 8K dual monitor KVM switch integrated with an 11-in-1 docking station. This all-in-one device enables users to control a desktop, a laptop, dual monitors, and multiple peripherals with ease—boosting productivity for office work, learning, and gaming.

AV Access, a leading provider of Pro AV and AV over IP solutions, proudly announces the launch of the iDock B10 8K KVM switch docking station. As the latest addition to its acclaimed iDock series, the iDock B10 delivers dual 8K@60Hz output, an 11-in-1 docking design, ultra-high refresh rates, and more—making it an ideal solution for professionals and gamers seeking seamless multitasking and immersive visual performance.

8K KVM Switch with 11-in-1 Docking Functionality

“In today’s hybrid work environment, flexibility is essential—especially for professionals such as graphic designers, software developers, and gaming enthusiasts,” said Bill Liao, CTO of AV Access. “The iDock B10 is designed to simplify complex setups, reduce desktop clutter, and significantly enhance workflow efficiency.”

The iDock B10 features one full-featured USB-C input port (with MST support) and a second input group consisting of HDMI, DisplayPort, and USB. This configuration allows users to connect and control both a laptop and a desktop simultaneously. It also offers a comprehensive range of connectivity options, including USB 3.0, USB 2.0, USB-C, Gigabit Ethernet, a 3.5mm audio jack, an SD card slot, HDMI output, and DisplayPort output.

Seamless Switching Between Work and Play

With its USB-C input, the iDock B10 supports 8K Ultra HD video input and data transfer speeds of up to 10Gbps. It also delivers up to 100W of power to charge laptops and provides reliable internet access to both the laptop and desktop via its Gigabit LAN port.

Users can switch between their laptop and desktop effortlessly using either the front panel button or the included wired remote controller. The iDock B10 also supports ultra-high refresh rates—including 4K@165Hz/144Hz, 2560×1440@144Hz/120Hz, and 1080P@240Hz/165Hz—ensuring fluid, responsive gameplay for high-speed simulations and competitive gaming.

“The iDock B10 USB-C KVM switch is now available on our official website at a launch price of $224.99, with a limited-time 10% discount,” added Bill Liao. “Together with other iDock series models like the iDock C10 and iDock C20, it’s an essential tool for anyone looking to streamline their workspace and switch effortlessly between work and play.”

About AV Access

AV Access is a global leader in advanced Pro AV and AV over IP solutions. Its product portfolio includes HDMI/KVM extenders, splitters, switchers, KVM switches, AV over IP solutions, and wireless conferencing systems. Since its founding, AV Access has been committed to delivering high-quality, user-friendly AV solutions at honest prices.

With a strong R&D foundation, robust supply chain, and experienced management team, AV Access continues to innovate across industries including smart home, corporate, education, retail, entertainment, and healthcare. Learn more at www.avaccess.com.

Media Contact
Company Name: Actions Global (US) Inc
Contact Person: Shane Jiang
Email: Send Email
Phone: +1-866-629-3923
Address:100 N HOWARD ST STE R
City: City of Spokane
State: Washington 99201
Country: United States
Website: https://www.avaccess.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AV Access Launches iDock B10: A Cutting-Edge 8K Dual Monitor KVM Switch Docking Station for Home Office & Gaming

Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross

The Key Sarcopenia Companies in the market include – TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others.

DelveInsight’s “Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Sarcopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sarcopenia Market Forecast

Some of the key facts of the Sarcopenia Market Report:

The Sarcopenia market size was valued ~USD 2,000 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2025, the Sarcopenia market size in the US was the largest among the 7MM, valued at around USD ~1,500 million, with further growth anticipated by 2034.
In April 2025, TNF Pharmaceuticals, Inc. announced that Mitchell Glass, M.D., President and Chief Medical Officer of TNF, delivered a platform presentation on the abstract titled “Isomyosamine for the Treatment of Sarcopenia in Older Adults” at the British Geriatrics Society (BGS) Spring Meeting 2025, which took place from April 9–11 in Belfast, Ireland, and online.
In December 2024, The US FDA awarded Fast Track Designation (FTD) to LPCN 1148 for the treatment of sarcopenia in patients with decompensated cirrhosis.
In December 2024, Epirium Bio, Inc. (Epirium) announced that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for MF-300, a novel, orally administered 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme inhibitor being developed to treat sarcopenia, which is age-related muscle weakness.
In December 2024, Lipocine announced that the US Food and Drug Administration (FDA) has awarded Fast Track Designation to LPCN1148 for the treatment of sarcopenia in patients suffering from decompensated cirrhosis.
Key companies developing therapies for sarcopenia include TNF Pharmaceuticals with MYMD-1/Isomyosamine, Biophytis with Sarconeos, and Lipocine with LPCN 1148. Additionally, several companies are working on early-stage sarcopenia treatments, such as ImmunoForge (Froniglutide), Rejuvenate Biomed (RJx-01), Keros Therapeutics (KER-065), and BPGbio (BPM 31510), along with others advancing their candidates through various stages of clinical development.
In 2024, the total number of diagnosed prevalent cases of sarcopenia across the 7MM was approximately 19,836,200, with projections indicating a rise throughout the study period (2020–2034).
In 2024, the UK had the highest number of diagnosed prevalent cases of sarcopenia among the EU4 and the UK, followed by Germany, while Spain reported the lowest number of cases.
In the US, sarcopenia cases are categorized by age groups: 65–69 years, 70–79 years, and 80 years and older. In 2024, the 65–69 age group had the highest number of cases, estimated at approximately 4,520,200.
In Japan, the estimated number of sarcopenia cases was around 5,225,100 in 2024.
Key Sarcopenia Companies: TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others
Key Sarcopenia Therapies: MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others
The Sarcopenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sarcopenia pipeline products will significantly revolutionize the Sarcopenia market dynamics.

Sarcopenia Overview

Sarcopenia is a condition characterized by the gradual loss of muscle mass, strength, and function, typically associated with aging. It can lead to physical frailty, reduced mobility, and an increased risk of falls and fractures. Sarcopenia is often diagnosed through a combination of muscle mass measurements and assessments of strength or physical performance. It can be influenced by factors such as inactivity, poor nutrition, chronic illness, and hormonal changes. Early detection and management through exercise, diet, and, in some cases, medication, can help mitigate its effects.

Get a Free sample for the Sarcopenia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/sarcopenia-market

Sarcopenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sarcopenia Epidemiology Segmentation:

The Sarcopenia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Sarcopenia
Prevalent Cases of Sarcopenia by severity
Gender-specific Prevalence of Sarcopenia
Diagnosed Cases of Episodic and Chronic Sarcopenia

Download the report to understand which factors are driving Sarcopenia epidemiology trends @ Sarcopenia Epidemiology Forecast

Sarcopenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sarcopenia market or expected to get launched during the study period. The analysis covers Sarcopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sarcopenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sarcopenia Therapies and Key Companies

MYMD-1/Isomyosamine: TNF Pharmaceuticals
LPCN 1148: Lipocine
Sarconeos (BIO101): Biophytis
Froniglutide (PF-1801): ImmunoForge
RJx-01: Rejuvenate Biomed
KER-065: Keros Therapeutics
BPM 31510 (ubidecarenone): BPGbio
OC514: Oncocross
MT29: Mirscience Therapeutics
TRN-005: Turn Biotechnologies
NMDP-05: NMD PHARMA
PF1807: ImmunoForge
DW1030: Dong Wha PHARM

Discover more about therapies set to grab major Sarcopenia market share @ Sarcopenia Treatment Landscape

Sarcopenia Market Strengths

Lifestyle modifications, including exercise and proper nutrition, have shown efficacy in preventing and managing sarcopenia.

Sarcopenia Market Opportunities

Improved integration of sarcopenia screening and management into routine healthcare practices can enhance early detection and intervention.

Scope of the Sarcopenia Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Sarcopenia Companies: TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others
Key Sarcopenia Therapies: MYMD-1/Isomyosamine, LPCN 1148, Sarconeos (BIO101), Froniglutide (PF-1801), RJx-01, KER-065, BPM 31510 (ubidecarenone), OC514, MT29, TRN-005, NMDP-05, PF1807, DW1030, and others
Sarcopenia Therapeutic Assessment: Sarcopenia current marketed and Sarcopenia emerging therapies
Sarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Sarcopenia Unmet Needs, KOL’s views, Analyst’s views, Sarcopenia Market Access and Reimbursement

To know more about Sarcopenia companies working in the treatment market, visit @ Sarcopenia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Sarcopenia Market Report Introduction

2. Executive Summary for Sarcopenia

3. SWOT analysis of Sarcopenia

4. Sarcopenia Patient Share (%) Overview at a Glance

5. Sarcopenia Market Overview at a Glance

6. Sarcopenia Disease Background and Overview

7. Sarcopenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Sarcopenia

9. Sarcopenia Current Treatment and Medical Practices

10. Sarcopenia Unmet Needs

11. Sarcopenia Emerging Therapies

12. Sarcopenia Market Outlook

13. Country-Wise Sarcopenia Market Analysis (2020–2034)

14. Sarcopenia Market Access and Reimbursement of Therapies

15. Sarcopenia Market Drivers

16. Sarcopenia Market Barriers

17. Sarcopenia Appendix

18. Sarcopenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross

JPI Investments Becomes the Leading European CFD Platform in Queensland’s Booming Retail Trading Market

As retail trading surges across Australia, Queensland has emerged as a particularly dynamic hub, with thousands of new investors seeking reliable and efficient platforms to access global financial markets. Among the many players attempting to capture this momentum, JPI Investments has taken a commanding lead, solidifying its position as the top-performing European CFD platform in the region.

Once known primarily in Central and Eastern Europe, JPI Investments has rapidly adapted its strategy to meet the expectations of the Australian retail sector, focusing on transparency, speed, and platform stability. With a localized onboarding process, 24/5 multilingual support, and a sharp focus on regulatory alignment, JPI now sets the standard for competitors in Queensland.

Why Queensland?

With Brisbane’s rise as a fintech-friendly city and an influx of young, tech-savvy investors across the Gold Coast and Sunshine Coast, Queensland has become a magnet for international brokers. The state boasts one of the highest retail trading participation rates per capita in Australia, thanks to high internet penetration, increasing financial literacy, and a growing appetite for alternative income streams.

European brokers have responded to this trend with enthusiasm, and JPI Investments has led the charge.

“Queensland has been a strategic priority for us,” said a company representative. “The local trader community is highly engaged, but also cautious — they’re looking for platforms they can trust. That’s where our reputation, performance metrics, and transparency give us an edge.”

The Current Leaderboard: Top CFD Platforms in Queensland (European-based)

According to internal market research, user feedback, and platform analytics, the top five European CFD platforms currently popular in Queensland are:

1. JPI Investments –

With its lightning-fast execution, intuitive platform, and growing support network in Australia, JPI leads the way. The company’s recent introduction of smart risk management tools and personalized analytics dashboards has further widened the gap between itself and competitors.

2. Valexio Markets –

A Cyprus-regulated firm offering broad asset coverage and well-rated educational content. Valexio is popular among beginner traders, but lags behind in terms of platform design and order execution speeds compared to JPI.

3. Finvaron Capital –

Known for its conservative approach and strong regulatory standing in Europe, Finvaron appeals to more risk-averse traders. However, the platform’s complexity and lack of user-friendly mobile tools make it less attractive to Queensland’s younger investor demographic.

4. TradeNest Europe –

With a modern user interface and wide asset availability, TradeNest has seen growth in Brisbane. Still, frequent downtime during volatile sessions and delays in support response have affected user sentiment.

5. OrionX Global –

A relative newcomer, OrionX targets millennial and Gen Z traders with gamified features and social copy trading. While innovative, it lacks the trust signals and infrastructure that seasoned investors seek.

What Sets JPI Apart?

Localized Support: JPI has hired Australian-based consultants to better serve local users and resolve issues in real time.

Regulatory Ambition: The company is in the process of applying for ASIC oversight, demonstrating its intent to fully integrate with the Australian financial system.

Tech Reliability: Unlike many offshore platforms, JPI boasts an industry-leading 99.98% uptime, crucial for fast-paced CFD trading.

Client-Centered Growth: JPI continuously evolves its offering based on trader feedback, including the launch of new tools like dynamic margin adjustment, AI-driven trade signals, and improved withdrawal automation.

Outlook: Leadership with Accountability

While some international firms focus solely on growth, JPI Investments emphasizes responsible expansion, working to ensure compliance, customer safety, and technological innovation. With the Australian market becoming increasingly selective about who they trust, JPI’s approach seems to be the right fit at the right time.

Whether this leadership will be sustained depends on how well the company continues to localize its offerings and respond to regulatory changes — but for now, JPI Investments stands as the undisputed European CFD leader in Queensland.

Learn more at: jpi-invest.org

For more details, contact Otto Walters at support@jpi-invest.org.

Address: High Street, Waltham Cross, Hertfordshire, United Kingdom, EN8 7AP

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: JPI Investments
Contact Person: Support
Email: Send Email
Country: United Kingdom
Website: jpi-invest.org

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: JPI Investments Becomes the Leading European CFD Platform in Queensland’s Booming Retail Trading Market

Darn Good Yarn Founder Nicole Snow Builds a Global, Eco-Friendly Craft Brand That’s Empowering Women Around the World

Darn Good Yarn, an award-winning sustainable yarn and upcycled fashion brand founded by U.S. Air Force veteran Nicole Snow, is redefining creativity with purpose. Specializing in recycled silk yarn, handmade craft kits, and eco-friendly clothing like its signature sari wrap skirts, the brand helps conscious consumers embrace a zero-waste lifestyle. Each product is crafted by women artisans in India and Nepal, blending fair trade practices with vibrant, one-of-a-kind materials that would otherwise be discarded.

Since launching in 2008, Darn Good Yarn has grown into a global eco-brand serving tens of thousands of creative customers with recycled silk yarn, upcycled clothing, fair trade fiber art tools, and handmade DIY craft kits. Every item is crafted by women artisans in India and Nepal using discarded sari fabric and other reclaimed materials, transforming textile waste into vibrant, purposeful goods. This artisan-led production model supports over 600 women in sustainable employment and has prevented more than 2 million pounds of waste from entering landfills and waterways worldwide.

Founder Nicole Snow, a U.S. Air Force veteran and lifelong creative, launched Darn Good Yarn with a bold mission: to reduce global textile waste and create sustainable jobs for women through the power of creativity. What began as a one-woman operation has grown into a woman-owned, family-run business based in Portsmouth NH, that champions fair trade yarn, artisan empowerment, and eco-conscious living. At its core, Darn Good Yarn is committed to radical transparency, ethical sourcing, and giving new life to materials once destined for the landfill.

“Our mission is to show that crafting and shopping sustainably can make a real difference,” said Nicole Snow, founder of Darn Good Yarn. “When you choose one of our recycled yarns, upcycled sari skirts, or handmade kits, you’re helping create fair-wage jobs for women and giving new life to materials that might otherwise end up in landfills.”

Based in the historic seacoast town of Portsmouth, New Hampshire, Darn Good Yarn is proud to serve a global community of conscious creatives from its charming brick-and-mortar fiber arts shop and online store. The brand is best known for:

Recycled silk yarn spun from reclaimed sari fabric—perfect for knitting, crochet, weaving, and mixed media art
Upcycled sari wrap skirts, handmade by women-led co-ops in India and Nepal—each one is a wearable work of art
Eco-friendly craft kits and fiber tools for beginner and seasoned makers, designed to spark creativity and mindfulness
An ethical supply chain model that champions artisan empowerment, year-round employment, and fair wages

Whether visiting the store in Portsmouth or shopping online, customers discover products that tell a story of sustainability, craftsmanship, and color.

With deep roots in the fiber arts, sustainable fashion, and zero-waste lifestyle movements, Darn Good Yarn continues to grow through a vibrant ecosystem of community-driven storytelling, passionate maker networks, and partnerships with like-minded creators and educators. Whether it’s a knitter discovering recycled yarn, a traveler falling in love with a sari wrap skirt, or a teacher using your DIY kits in the classroom, the brand thrives on connection, creativity, and impact.

As conscious consumerism, DIY creativity, and homesteading culture continue to rise, Darn Good Yarn leads the movement with products that are as purposeful as they are beautiful. From the studio to the garden shed, the brand empowers people to create with intention, shop with compassion, and feel good, knowing their choices support women, reduce waste, and celebrate color.

For media inquiries, product samples, or interview opportunities with Nicole Snow, please contact: dylan@evolpro.co

Media Contact
Company Name: Darn Good Yarn
Contact Person: Dylan Howard
Email: Send Email
Country: United States
Website: darngoodyarn.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Darn Good Yarn Founder Nicole Snow Builds a Global, Eco-Friendly Craft Brand That’s Empowering Women Around the World

Codex Labs to Exhibit at 2025 American Association of Naturopathic Physicians Annual Convention

Indian Wells, Calif. – July 8th, 2025 – Codex Labs, a biotech skincare company focused on microbiome-friendly solutions, is honored to participate in the American Association of Naturopathic Physicians (AANP) Annual Convention. From July 10th to 12th, naturopathic professionals will gather in Palm Springs at the Renaissance Esmeralda Resort, Indian Wells to explore the latest knowledge on a wide range of topics, including dietary interventions and supplements, women’s health and hormones, the microbiome, botanical medicine, and metabolic health.

AANP will feature networking sessions, round table discussions, lecture sessions, exhibitors, and more. Codex Labs will present a research poster titled “Botanical Moisturizer and Unscented Soap Improves Atopic Dermatitis and Itch” that will feature Codex Labs’ clinical data on the Bia Eczema Relief Lotion and Bia Unscented Soap and be displayed throughout the conference.

“This will summarize our clinical trial on the use of the Bia Eczema Relief Lotion and Bia Unscented Soap, where we found a 99% reduction in total mean SCORAD (a method of assessing eczema severity) in those with mild to moderate eczema,” says Dr. Jessica Maloh, Naturopathic Doctor and Head of Naturopathic Medicine at Codex Labs.

Dr. Maloh will also be giving a lecture on July 10th from 1:40 to 2:40 p.m. PT titled “Inside and Out Barrier Repair: The Gut-Skin Connection in Eczema and Acne.” This session will provide an evidence-based exploration of the gut-skin connection with a focus on eczema and acne. Dr. Maloh will discuss the latest research on the skin barrier, the skin microbiome, and their interplay with gut health.

Attendees will gain practical insights into inside and out management strategies, including dietary recommendations, supplements, topical interventions, and skin barrier-friendly habits.

“Dermatological conditions can have various causes and aggravators, and there is increasing research suggesting that a multi-faceted approach may optimize outcomes,” says Dr. Maloh. “I am so excited to discuss the latest data in the realm of integrative dermatology and to share practical takeaways with students and providers!”

AANP offers the opportunity to support and engage with industry leaders in naturopathic professions in an effort to advance naturopathic medicine, expand access to naturopathic doctors, and explore natural solutions. Codex Labs is honored to participate in the event and looks forward to showcasing its products and findings.

Codex Labs invites all event guests to visit their conference booth and poster to learn more about their latest skincare breakthroughs and receive samples from the Shaant, Antu and Bia collections.

Event Details:

Dates: July 10th-12th, 2025
- July 10th, 7:30 a.m. – 6:00 p.m. PST
  - Dr. Maloh’s Presentation: 1:40 p.m. – 2:40 p.m. PST
- July 11th, 8:00 a.m. – 9:00 p.m. PST
- July 12th, 8:00 a.m. – 7:30 p.m. PST
Location: 44400 Indian Wells Ln, Indian Wells, CA, 92210

For more information about Codex Labs and its products, please visit www.codexlabscorp.com. If you are interested in learning more about Codex Labs’ participation in AANP, please contact annakate.womack@otterpr.com.

About Codex Labs:

Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain-biome solutions that contain potent, biotech-derived plant-based actives. Codex Labs’ products focus on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema, and psoriasis. The brand has been heralded by integrative dermatologists and naturopathic doctors for creating the next generation of effective, vegan, cruelty-free, and sustainable plant-based solutions.

Media Contact
Company Name: Otter Public Relations
Contact Person: Anna Kate Womack
Email: Send Email
Phone: 7032323140
City: ORLANDO
State: FL
Country: United States
Website: www.otterpr.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Codex Labs to Exhibit at 2025 American Association of Naturopathic Physicians Annual Convention

Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth (ADIA, FATE, MESO, CRSP)

Regenerative medicine is gaining serious momentum in 2025 as scientific advances, regulatory progress, and payer acceptance converge to push the sector into a new growth phase. The global regenerative medicine market, valued at nearly $28 billion in 2024, is projected to grow at over 16% annually through 2030, driven by rising demand for cell and gene therapies that address autoimmune, degenerative, and rare diseases.

This year, we are seeing breakthroughs that remove long-standing barriers, including increased insurance coverage for stem cell therapies and accelerated clinical trial readouts for off-the-shelf cellular immunotherapies. Regulatory agencies are granting designations that streamline approval pathways while companies scale manufacturing capabilities to meet growing patient demand.

The result is a landscape primed for growth, with established players and innovative newcomers competing to deliver life-changing treatments with broader access and lower costs. Let’s take a look at four emerging players in regenerative medicine, each advancing promising therapies and carving out positions in this fast-evolving sector.

Adia Nutrition Inc. (OTCQB: ADIA) is moving aggressively to capture market share in regenerative medicine, and recent developments suggest the company may be on the cusp of a breakout. With a growing chain of clinics under its Adia Med division and a standout supplement line, Adia is uniquely positioned at the intersection of wellness, biotech, and clinical care. Its regenerative therapies focus on umbilical cord stem cells and autologous hematopoietic stem cell transplantation (aHSCT), two areas gaining momentum in the treatment of autoimmune and degenerative conditions. Now, the company is achieving something that has long eluded others in this space: mainstream insurance access.

In mid-June, ADIA announced that its Winter Park clinic in Florida had received full approval from the state’s Agency for Health Care Administration. The approval allows the clinic to accept insurance, transforming the economics of care for patients and providers alike. This opens access to life-changing treatments such as aHSCT and therapeutic plasma exchange (TPE), with patients no longer required to pay entirely out of pocket. It also elevates Adia Med’s credibility by confirming that its clinical operations meet the stringent healthcare standards enforced by the state of Florida. As insurance adoption continues to be one of the most important barriers in stem cell care, this approval is a major breakthrough and puts Adia ahead of many peers.

With this insurance access in place, Adia could rapidly grow its patient base, drive recurring revenue from covered procedures, and build a sustainable platform across multiple locations.

At the same time, ADIA is expanding its national footprint in another key way: public visibility. On June 24, the company launched its first national TV commercial for Adia Vita, its high-dose stem cell and exosome therapy. The ad is running on connected TVs through MNTN, a performance marketing platform known for its precision targeting. Adia Vita delivers 100 million stem cells and 3 trillion exosomes per dose, positioning it as a standout in a crowded, often unregulated market. While many stem cell products struggle with consistency and questionable sourcing, Adia Vita is manufactured through Adia Labs, an FDA-registered and cGMP-compliant facility. Physicians are legally allowed to use it off-label, empowering them to incorporate the therapy into patient care when appropriate. The commercial educates consumers while directing them to speak with their doctors, an approach that balances medical integrity with patient empowerment. More than a brand campaign, it signals Adia’s intent to lead the stem cell space with science, professionalism, and reach.

Earlier this year, ADIA uplisted to the OTCQB Venture Market in just six weeks, which is well below industry norms, and completed SEC Rule 15c2-11 compliance to ensure transparency for investors. These milestones laid the groundwork for the institutional credibility it is now leveraging in its clinical and commercial strategies. In parallel, Adia has signed international licensing deals with clinics in Mexico, Colombia, and the U.S., allowing partners to offer Adia Med therapies under its brand with strict quality control and exclusive access to products like Adia Vita and AdiaLink. To improve accessibility, Adia also introduced Cherry Payment Plans, offering flexible monthly installments to patients seeking treatment.

In an industry often defined by hype and regulatory hurdles, Adia Nutrition is quietly stacking real-world wins. With insurance-backed treatments, national exposure, and a scalable model already in motion, the company is shaping up to be a serious contender in the next phase of regenerative medicine.

Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company pioneering off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs). By engineering master iPSC lines, Fate creates uniform, ready-to-use cell products designed to tackle cancer and autoimmune diseases. Their approach allows for scalable manufacturing, potentially lowering costs and improving patient access compared to traditional personalized cell therapies.

The company’s pipeline includes FT819, an off-the-shelf CAR T-cell therapy targeting CD19, currently in Phase 1 trials for moderate-to-severe systemic lupus erythematosus (SLE) and lupus nephritis. Early clinical data presented at the 2025 EULAR Congress show promising results: all five patients treated achieved significant disease improvements with either reduced or no chemotherapy conditioning. One patient reached durable drug-free remission after 12 months. The therapy demonstrated a strong safety profile with no severe adverse events and only mild cytokine release syndrome in one case. These findings position FT819 as a potential breakthrough treatment that combines CAR T-cell efficacy with the convenience and accessibility of biologics.

Financially, Fate reported first-quarter 2025 revenue of $1.63 million and a net loss of $37.6 million, improving from the previous year. The company beat analyst expectations on both revenue and earnings per share and expects revenue growth to accelerate well above the biotech industry average in the coming years.

Fate is expanding its clinical program for FT819 into additional autoimmune indications, including systemic sclerosis and vasculitis, with regulatory discussions underway. The company’s proprietary iPSC platform and deep patent portfolio support its strategy to develop scalable, versatile cell therapies. As the field of stem cell-based immunotherapy evolves, Fate Therapeutics stands out with its unique off-the-shelf approach and encouraging early clinical results that may unlock new treatment options for challenging autoimmune diseases.

Mesoblast (NASDAQ: MESO) is advancing the field of regenerative medicine with meaningful traction across both regulatory and commercial fronts. Its lead therapy, Ryoncil, is the first mesenchymal stromal cell (MSC) product to receive FDA approval, offering a new treatment option for children with steroid-refractory acute graft versus host disease (SR-aGvHD). Now commercially available, Ryoncil is already covered by Medicaid in most U.S. states and will receive full national Medicaid coverage starting in July. The company estimates more than 220 million Americans now have insurance access to the product through public and private plans.

Uptake is progressing quickly. More than 20 transplant centers have already onboarded since the therapy’s launch this spring. A key advantage of Ryoncil lies in its ready-to-use, off-the-shelf formulation, which delivers powerful immunomodulatory effects for high-risk patients. With seven years of FDA orphan-drug exclusivity and intellectual property protections into the 2040s, Mesoblast has secured a strong commercial runway.

Beyond Ryoncil, Mesoblast is also working closely with the FDA to advance Revascor, a treatment for ischemic heart failure. A recent regulatory meeting clarified the pathway toward a potential accelerated approval. The company is also preparing to expand Ryoncil’s use to adult patients through a pivotal trial in partnership with the NIH.

Mesoblast has built its pipeline around a scalable platform of allogeneic cell therapies aimed at inflammation-related diseases. With robust payer support, expanding hospital use, and regulatory clarity on multiple fronts, the company is turning a science-led strategy into a commercial success story. Investors watching the growth of cellular medicine now see Mesoblast as one of the most active players making it real for patients today.

CRISPR Therapeutics AG (NASDAQ: CRSP) stands at the forefront of gene editing and stem cell innovation, building a diverse pipeline that targets some of the most challenging diseases. The company’s landmark achievement came with the approval of CASGEVY, the first CRISPR-based therapy authorized to treat sickle cell disease and transfusion-dependent beta thalassemia. This milestone validates CRISPR’s powerful technology and opens the door for broader applications in regenerative medicine.

One of the company’s most promising programs is CTX310, which targets the ANGPTL3 gene. This gene plays a key role in controlling blood lipids such as triglycerides and low-density lipoprotein cholesterol, major risk factors for cardiovascular disease. Early clinical data show CTX310 can lower triglycerides by as much as 82 percent and LDL cholesterol by up to 81 percent. The treatment has demonstrated a strong safety profile, making it a compelling candidate for patients with limited options.

Another program, CTX320, focuses on reducing elevated lipoprotein(a), a genetic risk factor linked to heart disease that currently has no approved therapies. Clinical trials are underway, positioning CRISPR to address a large unmet medical need.

In addition, a strategic collaboration with Sirius Therapeutics expands CRISPR’s reach into RNA interference therapies, with SRSD107 targeting thromboembolic disorders through a novel approach designed for better patient compliance and safety.

CRISPR Therapeutics has nearly 1.86 billion dollars in cash and equivalents to fund ongoing research and commercialization efforts. With an expanding pipeline, growing clinical validation, and solid finances, CRISPR is well-positioned to capitalize on the rapidly growing stem cell and gene editing market.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA Nutrition Inc. to assist in the production and distribution of this content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Small Caps, Big Potential: Regenerative Medicine Stocks Positioned for Growth (ADIA, FATE, MESO, CRSP)

Cholangiocarcinoma Market Insights 2034: Medication, EMA, PDMA, FDA Approvals, Clinical Trials, Treatment Market, Epidemiology, NICE Approvals, Therapies, Companies by DelveInsight

“Cholangiocarcinoma Market”

The cholangiocarcinoma market is driven by chemotherapy dominance, with the US leading in size. In 2023, ~45,000 cases occurred in the 7MM, 45% intrahepatic, mainly in those 80+. TP53 & KRAS mutations are common. ~80% receive adjuvant therapy. Key drugs include PEMAZYRE, TIBSOVO & LYTGOBI. Senhwa’s CX-4945 may gain future share. Biosyngen’s BST02 got FDA FTD in 2024. With active pipelines, the market outlook through 2034 is positive amid strong pharma interest.

(Albany, USA) DelveInsight’s “Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Cholangiocarcinoma, historical and forecasted epidemiology as well as the Cholangiocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Cholangiocarcinoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Cholangiocarcinoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Cholangiocarcinoma market.

Request for a Free Sample Report @ Cholangiocarcinoma Market Forecast

Some facts of the Cholangiocarcinoma Market Report are:

According to DelveInsight, Cholangiocarcinoma market size is expected to grow at a decent CAGR by 2034.
In 2021, the total Cholangiocarcinoma market size was USD 786.1 million which is expected to rise during the study period (2020-2034).
Leading Cholangiocarcinoma companies working in the market are AstraZeneca, Decalth Systems, Power Life Sciences, Genfit, Servier Affaires Médicales, Basilea Pharmaceutica, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals, Servier Pharmaceuticals, and Others.
Key Cholangiocarcinoma Therapies expected to launch in the market are PEMAZYRE (pemigatinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), and others.
In May 2025, Tango Therapeutics Inc. announced a study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
In April 2025, Servier (Servier Affaires Médicales) announced an Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
In February 2025, Eisai Inc. announced results of a Multicenter, Open-Label, Phase 2 Trial of E7090 in Subjects With Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR 2 Gene Fusion
In January 2025, Servier announced results of a Phase 2, Open-label, Multicenter Study of Orally Administered Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
In December 2024, Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company revolutionizing drug discovery through advanced computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. focused on improving treatment outcomes for patients with limited therapeutic options, announced today an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The partnership follows Relay’s recent positive FDA interaction and previously reported promising data in cholangiocarcinoma and other solid tumors.
In September 2024, Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to certepetide for the treatment of cholangiocarcinoma.
On March 2024, Genfit announced an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy.
On Feb 2024, TransThera Sciences (Nanjing), Inc announced a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
On March 2023, Power Life Sciences Inc announced a Clinical Study Experiences of Cholangiocarcinoma Patients to Identify Trial Attributes Affecting Completion Rates for Specific Demographic Groups.

Learn more about Cholangiocarcinoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Cholangiocarcinoma Treatment Market

Cholangiocarcinoma Overview

Cholangiocarcinoma, also known as bile duct cancer, is a rare but aggressive form of cancer originating in the bile ducts, which transport bile from the liver to the small intestine. This cancer is classified into three types based on its location: intrahepatic (within the liver), perihilar (at the liver’s hilum), and distal (further down the bile duct). The majority of cholangiocarcinomas are adenocarcinomas, which arise from the mucus glands in the bile duct.

Risk factors for cholangiocarcinoma include primary sclerosing cholangitis, chronic liver disease, bile duct cysts, liver flukes, and certain genetic conditions. Symptoms often appear late and may include jaundice, abdominal pain, weight loss, and itching, making early detection challenging.

Diagnosis typically involves imaging studies such as MRI, CT scans, and cholangiography, along with biopsy and blood tests. Treatment options vary depending on the cancer’s stage and location but may include surgery, radiation therapy, chemotherapy, and targeted therapies. Liver transplantation is an option for some patients with early-stage disease.

Despite advances in treatment, the prognosis for cholangiocarcinoma remains poor, emphasizing the need for ongoing research and improved therapeutic strategies. Early diagnosis and multidisciplinary care are crucial for enhancing patient outcomes.

Request for Sample Report @ Cholangiocarcinoma Drugs Market

Cholangiocarcinoma Market

The Cholangiocarcinoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Cholangiocarcinoma market trends by analyzing the impact of current Cholangiocarcinoma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

The cholangiocarcinoma market is driven by rising incidence in the aging population, growing awareness, advances in diagnostics, and the development of targeted therapies addressing specific mutations like FGFR, IDH1, and others. The approval of drugs such as PEMAZYRE, TIBSOVO, and LYTGOBI reflects this momentum. However, market growth faces barriers including late-stage diagnosis limiting surgical eligibility, high treatment costs, modest survival benefits of current therapies, and the complex tumor biology that hinders drug development.

According to DelveInsight, the Cholangiocarcinoma market in 7MM is expected to witness a major change in the study period 2020-2034.

Cholangiocarcinoma Epidemiology

The Cholangiocarcinoma epidemiology section provides insights into the historical and current Cholangiocarcinoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Cholangiocarcinoma market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Cholangiocarcinoma Epidemiology @ Cholangiocarcinoma Market Dynamics and Trends

Cholangiocarcinoma Drugs Uptake

This section focuses on the uptake rate of the potential Cholangiocarcinoma drugs recently launched in the Cholangiocarcinoma market or expected to be launched in 2020-2034. The analysis covers the Cholangiocarcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Cholangiocarcinoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Cholangiocarcinoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cholangiocarcinoma Therapies and Key Companies

PEMAZYRE (pemigatinib): Incyte
TIBSOVO (ivosidenib): Agios Pharmaceuticals/Servier Pharmaceutical
LYTGOBI (futibatinib): Taiho Pharma
Imfinzi (durvalumab): Astrazeneca
Melphalan: Decalth Systems
Derazantinib: Basilea Pharmaceuticals
Futibatinib (TAS-120): Taiho Oncology
E7090: Eisai Pharmaceuticals
TT-0040: TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma Pipeline Development Activities

The Cholangiocarcinoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Cholangiocarcinoma key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Cholangiocarcinoma pipeline development activities @ Cholangiocarcinoma Clinical Trials and FDA Approvals

Cholangiocarcinoma Therapeutics Assessment

Major key companies are working proactively in the Cholangiocarcinoma Therapeutics market to develop novel therapies which will drive the Cholangiocarcinoma treatment markets in the upcoming years are AstraZeneca (LSE: AZN), Decalth Systems (Private), Power Life Sciences (Private), Genfit (EPA: GNFT), Servier Affaires Médicales (Private), Basilea Pharmaceutica (SWX: BSLN), Taiho Oncology (Private), Eisai Pharmaceuticals (TYO: 4523), TransThera Sciences (Private), Incyte Corporation (NASDAQ: INCY), Roche (SWX: ROG), Agios Pharmaceuticals (NASDAQ: AGIO), Servier Pharmaceuticals (Private), and others.

Cholangiocarcinoma Report Key Insights

1. Cholangiocarcinoma Patient Population

2. Cholangiocarcinoma Market Size and Trends

3. Key Cross Competition in the Cholangiocarcinoma Market

4. Cholangiocarcinoma Market Dynamics (Key Drivers and Barriers)

5. Cholangiocarcinoma Market Opportunities

6. Cholangiocarcinoma Therapeutic Approaches

7. Cholangiocarcinoma Pipeline Analysis

8. Cholangiocarcinoma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Cholangiocarcinoma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Cholangiocarcinoma Competitive Intelligence Analysis

4. Cholangiocarcinoma Market Overview at a Glance

5. Cholangiocarcinoma Disease Background and Overview

6. Cholangiocarcinoma Patient Journey

7. Cholangiocarcinoma Epidemiology and Patient Population

8. Cholangiocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Cholangiocarcinoma Unmet Needs

10. Key Endpoints of Cholangiocarcinoma Treatment

11. Cholangiocarcinoma Marketed Products

12. Cholangiocarcinoma Emerging Therapies

13. Cholangiocarcinoma Seven Major Market Analysis

14. Attribute Analysis

15. Cholangiocarcinoma Market Outlook (7 major markets)

16. Cholangiocarcinoma Access and Reimbursement Overview

17. KOL Views on the Cholangiocarcinoma Market

18. Cholangiocarcinoma Market Drivers

19. Cholangiocarcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cholangiocarcinoma Market Insights 2034: Medication, EMA, PDMA, FDA Approvals, Clinical Trials, Treatment Market, Epidemiology, NICE Approvals, Therapies, Companies by DelveInsight

123 Portable Toilet Rental Expands National Sanitation Services with Human-Centered Upgrades

123 Portable Toilet Rental has broadened its lineup of sanitation solutions to better fit the varied demands of outdoor gatherings, building projects, and emergency relief efforts across the country. Drawing on field-tested expertise and feedback from onsite managers, the company has refined its fleet, logistics, and support processes, making it easier for event organizers and site supervisors to keep facilities running smoothly.

Durable Units for Construction Sites

Tougher jobsite conditions call for fixtures that won’t quit in the face of heavy use or harsh weather. The newly enhanced Construction Portable Toilet series features reinforced walls, skid-resistant floors, and upgraded ventilation stacks. Site supervisors will appreciate the clear service schedules, which are mapped to project milestones, helping them maintain cleanliness benchmarks without the headache of unplanned downtime.

Specialized Options for Public Gatherings

Outdoor celebrations and large-scale events demand both function and a touch of comfort. To address this, the Event Toilet collection now includes models outfitted with easy-access handwashing stations, interior LED task lights, and splash-resistant dispensers. Support staff coordination ensures restocking and maintenance occur discreetly, allowing attendees to focus on the experience rather than restroom logistics.

Comfortable Trailer Solutions

When a more refined setup becomes necessary—whether for VIP zones, film crews, or emergency-response centers—the Restroom Trailer lineup delivers. These towable units come equipped with flushing toilets, running water sinks, climate controls, and private changing areas. Pull-up power connections and modular interiors simplify setup, transforming temporary quarters into spaces that feel more like a permanent facility.

Ensuring Accessibility for All

Equitable access to sanitation remains a key priority. The expanded Ada Portable Toilet fleet consists of ground-level entry models with ample interior room, sturdy grab bars, and wide, swing-open doors. These units are now routinely dispatched to community fairs, construction sites, and relief operations, helping to uphold inclusive standards without extra administrative hurdles.

Core Rental Services and Seamless Coordination

At the heart of the operation lies a dependable Portable Toilet Rental network that covers small-scale projects up to multi-venue events. Real-time tracking tools provide clear delivery and pickup windows, reducing surprises on tight timelines. Customer-service liaisons utilize consolidated order portals to synchronize unit counts with fluctuating attendance figures or evolving work phases.

About 123 Portable Toilet Rental

123 Portable Toilet Rental operates a fully licensed, insured, and nationally recognized fleet of sanitation units, trailers, and accessories. Through advanced logistics planning and ongoing training for field technicians, the company supports a broad spectrum of industries—from construction and hospitality to disaster relief and public festivals—helping ensure clean, safe facilities wherever they’re needed.

Media Contact
Company Name: 123 Portable Toilet Rental
Contact Person: Sean Mahon
Email: Send Email
Phone: (866) 791-2759
Country: United States
Website: https://www.123portabletoiletrental.com/

Not All Critical Mineral Stocks Are Created Equal-SAGA Metals Proves That Point

Investors have long maintained a decades-long affection for precious metals stocks. They’re high-risk, high-reward. But if they hit, the ROI can be exponential. That same appreciation is now reaching a new class of underground assets—critical minerals. As global priorities shift toward electrification, grid stability, and reshored supply chains, companies exploring for vanadium, titanium, and other strategic metals have become red-hot additions to smartly assembled growth stock portfolios.

Still, it’s worth remembering that not all critical mineral stocks are created equally. Most exploration-stage stories fall into two camps: overhyped and underfunded, or legitimate—but already overrun by early institutional entrants. That’s what makes SAGA Metals Corp. (TSXV: SAGA | OTCQB: SAGMF | FSE: 20H) a rare standout. We’ve covered their assets before. It’s a microcap with scale, grade, 100% ownership rights, and the kind of real-world relevance that few juniors can match—and it still flies under the radar. But likely not for long.

That’s because the company’s Radar Ti-V-Fe Project in Labrador, Canada, isn’t just another promising land package—it’s an entire geologic system now under complete SAGA control. Following its May acquisition of 97 new claims, SAGA became the sole owner of the entire Dykes River layered mafic intrusive complex, a 160-square-kilometer titanomagnetite-bearing system enriched with vanadium, titanium, and iron. That level of consolidation at this stage of development is virtually unheard of. It turns SAGA from a one-project explorer into a full-scale platform play with massive leverage—and growing interest.

Video Link: https://www.youtube.com/embed/5eOJ3WGyrcc

Proof Through Structure, Not Hype

SAGA’s not pitching a theory. It’s revealing a structure. That’s the real takeaway from the company’s 2025 winter drill campaign at the Hawkeye Zone—a 500m x 350m sub-section of the broader Radar project. There, SAGA drilled seven core holes totaling 2,200 meters and confirmed what few juniors can on a first pass: massive to semi-massive oxide layering consistent with large-scale, economically significant vanadiferous titanomagnetite systems.

These results aren’t just high-grade—they’re layered, consistent, and aligned with surface mapping and airborne magnetic data. While technical jargon to most, the highlights include:

31.5m @ 25.95% Fe, 5.34% TiO₂, 0.28% V₂O₅ (HEZ-01)
50m @ 24.49% Fe, 4.74% TiO₂, 0.305% V₂O₅ (HEZ-04)
28m @ 20.11% Fe, 4.22% TiO₂, 0.214% V₂O₅ (HEZ-06)
133m of continuous mineralization averaging over 4% TiO₂ in HEZ-02

In simpler speak, it’s excellent news. And it’s led to SAGA’s technical team identifying four distinct VTM (vanadiferous titanomagnetite) layering sequences within Hawkeye alone—each with the kind of predictability and geophysical correlation that allows targeting to become increasingly efficient going forward. The best part? Hawkeye represents just 1/40th of the 20-kilometer magnetic strike.

And this system is clean.

SAGA’s mineralogy is dominated by titanomagnetite—a phase that simplifies downstream metallurgy and supports the production of high-grade, low-impurity concentrates. Early petrography already confirms its suitability for strategic-grade vanadium, titanium dioxide, and iron. And it gets better. SAGA is now testing for secondary minerals like phosphate, scandium, manganese, and rare earth elements—potential value multipliers that could dramatically reshape the economic profile of the deposit.

In short, this isn’t just a mineralized zone. As the company spells out, it’s a structurally coherent, metallurgically elegant system—one that’s scalable, efficient, and ready for the next phase of growth.

A Clean Project in a Clean Jurisdiction

Know this, too: Yes, the minerals are important. Yes, the structure is excellent. But the location also matters. And SAGA’s advantage is geographic as much as it is geologic.

Radar sits just 10 kilometers from Cartwright, Labrador, providing the project with immediate access to road networks, a deep-water port, local hydropower, and a community with experience in hosting industrial activity. For critical minerals, where permitting, ESG scrutiny, and geopolitical stability now dictate capital flow, this is the right ZIP code.

It’s one of the few regions where a high-grade, North American feedstock for vanadium and titanium can be commercially advanced—and SAGA controls every square meter of it.

That full-system ownership isn’t just a bragging right. It’s a competitive moat. Unlike many juniors juggling fractured land packages or speculative joint ventures, SAGA isn’t negotiating access or splitting returns. Its clean structure is ideal for downstream strategic partners—defense, aerospace, and green steel—who need not only a product but also a traceable, ESG-compliant product.

The roadmap from here is clear. With Hawkeye now de-risked, SAGA is expanding geophysical surveys, mapping new magnetic anomalies, and preparing to drill its next high-priority zone: Trapper, which shows even stronger signals than Hawkeye. At the same time, metallurgical studies are advancing, designed to define not only recoveries but also the optimal economic pathway to commercialization. In other words, SAGA is now a “how big, how clean, how fast” story.

Growth Trajectory Can Steepen Share Price

And the valuation? Still stuck in microcap territory. Perhaps not for much longer.

Peers with weaker geology, murkier jurisdiction, and fractured ownership regularly command market caps of $50M–$100M. SAGA remains significantly below that. However, that disconnect isn’t likely to persist once the next drill phases confirm what the geophysics already suggest: that SAGA presents one of the most scalable critical minerals systems in eastern Canada—and one of the most overlooked.

The good news? If you’re reading this, you’re early to the value proposition.

Retail investors rarely get the first shot at fully consolidated, clean-ownership, drill-verified geologic systems with this kind of upside. But SAGA Metals is still below the radar—for now. And more likely than not, strategic partners are circling. From there, institutions typically follow.

Once that wave of interest hits, the bargain prices could be gone. Better said, for those wanting in on a booming critical minerals sector, consider SAGA sooner rather than later.

Sources and references:

https://SAGAmetals.com/projects/
https://SAGAmetals.com/SAGA-metals-and-rio-tinto-sign-option-to-joint-venture-agreement-for-lithium-asset-in-eastern-james-bay-quebec/
https://SAGAmetals.com/investment-highlights/
https://SAGAmetals.com/corporate-presentation/
https://finance.yahoo.com/quote/SAGMF/history/

Disclaimer and disclosures:This Disclaimer and Disclosure statement is a permanent part of this content. Any reproduction of this content that does not include the Disclaimer and Disclosure statement is unauthorized and strictly prohibited. All investments are subject to risk, which must be considered on an individual basis before making any investment decision. This paid advertisement includes a stock profile of SAGA Metals Corp. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to sell or a solicitation of an offer to purchase any securities. In an effort to enhance public awareness, Hawk Point Media Group, Llc. was hired by Shore Thing Media Group, Llc. to create and distribute digital content for SAGA Metals Corp. Shore Thing Media Group, Llc. compensated Hawk Point Media Group, Llc. USD five-thousand-dollars via wire transfer to complete and distribute these services. This advertisement is being disseminated for a period of one month beginning on 06/24/25 and ending on 07/23/25. Hawk Point Media Group, Llc. owners, officers, principals, affiliates, contributors, and/or related parties do not own, intend to own, sell, or intend to sell SAGA Metals Corp. stock. However, it is prudent to expect that those hiring Hawk Point Media Group, Llc, including that company’s owners, employees, and affiliates may sell some or even all of the SAGA Metals Corp. shares that they own, if any, during and/or after this engagement period. If successful, this advertisement will increase investor and market awareness of SAGA Metals Corp. and its securities, which may result in an increased number of shareholders owning and trading the securities, increased trading volume, and possibly an increase in share price, which may be temporary. This advertisement does not purport to provide a complete analysis of SAGA Metals Corp. or its financial position. The agency providing this content are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a registered broker-dealer or registered investment advisor or, at a minimum, doing your own research if you do not utilize an investment professional to make decisions on what securities to buy and sell, and only after reviewing the financial statements and other pertinent publicly-available information about SAGA Metals Corp. Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in SAGA Metals Corp. SEC filings. Investing in microcap securities such as SAGA Metals Corp. is speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, Hawk Point Media Group, Llc. cannot guarantee the accuracy or completeness of the information and are not responsible for any errors or omissions. This advertisement contains forward-looking statements, including statements regarding expected continual growth of SAGA Metals Corp. and/or its industry. Hawk Point Media Group, Llc. note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect SAGA Metals Corp. actual results of operations. Factors that could cause actual results to vary include the size and growth of the market for SAGA Metals Corp. products and/or services, the company’s ability to fund its capital requirements in the near term and long term, federal and state regulatory issues, pricing pressures, etc. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. Hawk Point Media Group, Llc. are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Not All Critical Mineral Stocks Are Created Equal-SAGA Metals Proves That Point

Lift Away Junk Removal Helps Rockaway Homeowners and Businesses Stay Safe and Clutter-Free

Lift Away Junk Removal, owned by Vincent Prezioso, provides respectful, eco-conscious junk removal in Rockaway, NJ, for homes and businesses. With trained, background-checked crews and a focus on donation and recycling, the company helps clients declutter safely and responsibly. Services include cleanouts, office hauling, and estate cleanups, with every job handled as carefully as their own space.

Rockaway, NJ – Lift Away Junk Removal is helping Rockaway residents and businesses take back control of their space with professional junk removal services that are fast, respectful, and community-focused. As demand continues to grow for clean, organized environments, the locally owned company is setting itself apart through its “donate first, recycle second, dispose last” approach to hauling unwanted items.

Owned by Vincent Prezioso, Lift Away Junk Removal serves homes, offices, and commercial properties across northern New Jersey. With a fully trained, background-checked team and a commitment to treating every space with care, the company is becoming the go-to solution for junk removal in Rockaway.

“Our goal is to make junk removal simple, respectful, and environmentally responsible,” said Prezioso. “Whether it’s a garage full of old boxes or an office renovation, we handle it like it’s our own space.”

Safe, Reliable Service from a Local Team You Can Trust

Every team member at Lift Away Junk Removal is fully trained and background-checked before stepping foot on a client’s property. The company emphasizes safety, professionalism, and customer care, making it ideal for homeowners, families, seniors, and business owners who want to feel confident about who they invite into their space.

From start to finish, customers receive a consistent, respectful experience. The team arrives on time, works quickly, and makes sure every area is left clean. All items are sorted according to the company’s disposal philosophy: donate what can be reused, recycle what can’t be donated, and dispose of only what’s necessary.

This method not only reduces waste but also supports local charities and keeps usable items out of landfills.

Serving Homes and Offices Across Rockaway

Lift Away Junk Removal provides a wide range of services to meet the needs of both residential and commercial clients. Common requests include:

Full-home and garage cleanouts

Office furniture and electronics removal

Attic and basement junk hauling

Yard debris and bulk item pickup

Storage unit cleanouts

Estate cleanouts and senior downsizing

The company has seen growing demand for junk removal in Rockaway, particularly from families preparing to move, seniors organizing their homes, and businesses updating their spaces.

“We’re seeing more people ready to reclaim their space, and they just need the right help,” said Prezioso. “That’s where we come in.”

Customers can view reviews and learn more about the company’s reputation on its Google Business Profile.

Donation and Recycling Come First

Lift Away Junk Removal leads with purpose. Whenever possible, items are donated to local organizations that help people in need. Furniture, clothing, appliances, toys, books, and even building materials can be directed to donation partners rather than discarded.

Recycling is the next step in the process. Materials like metal, paper, cardboard, and certain plastics are properly sorted and dropped off at local recycling centers. Only after donation and recycling are ruled out does anything get taken to a landfill.

This environmentally mindful process has made the company popular with clients who want to reduce their impact while decluttering their homes or offices.

Tailored Service with a Focus on Respect

Vincent and his team are committed to providing service that goes beyond hauling junk. Every interaction is built on trust, care, and attention to detail. Whether a customer needs one item picked up or an entire property cleared, the Lift Away team adjusts to the job size with the same level of dedication.

The company has become known for its clear communication, straightforward pricing, and no-surprise service.

“We know we’re stepping into people’s homes and personal spaces,” said Prezioso. “We don’t take that lightly. We treat every job with the same care we’d want for our own families.”

Book Junk Removal with a Purpose

For Rockaway residents and business owners looking for a reliable junk hauling partner, Lift Away Junk Removal offers a combination of professionalism, speed, and community responsibility. Whether it’s one piece of furniture or a full-scale cleanout, the team is ready to help.

About Lift Away Junk Removal

Lift Away Junk Removal is a locally owned junk removal company based in Rockaway, NJ and serving the surrounding northern New Jersey area. Founded by Vincent Prezioso, the company specializes in residential and commercial junk hauling with an emphasis on donation, recycling, and minimal landfill disposal. With fully trained and background-checked crews, Lift Away Junk Removal delivers fast, respectful service built on trust and environmental responsibility.

Media Contact
Company Name: Lift Away Junk Removal
Contact Person: Vincent Prezioso
Email: Send Email
Phone: 973-545-7177
Address:16 Green Pond Road
City: Rockaway
State: NJ
Country: United States
Website: https://liftawayjunk.com/